Denosumab for Type 1 Diabetes | MicrobiomeTrials← Back to trialsNCT06524960
Denosumab for Type 1 Diabetes
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2024-09-03Est. Completion: 2027-10-11
Enrollment target: 45 participants Locations- University of Alabama at Birmingham, Birmingham, Alabama, United States
- City of Hope Medical Center, Duarte, California, United States
- Indiana University, Indianapolis, Indiana, United States
Other microbiome trials you might be interested in
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Type 2 Diabetes Mellitus (T2DM) is a progressive metabolic disease, often compounded by obesity, that leads to serious l…
Multiple LocationsEst. completion Jan 12, 2027
Non-alcoholic Fatty Liver Disease
The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis…
Chandler, United StatesEst. completion Mar 29, 2028
A 12-month randomized, controlled, parallel-arm trial, divided into 2 consecutive periods: (1) 6-month weight loss perio…
Chicago, United StatesCompleted Feb 1, 2025